Jun 2026 (Q2 FY26) — Aug 5, 2026
Elanco Q2 FY26 — Strong Innovation-Led Growth and Raised Full-Year Outlook
Read the full callElanco (ELAN) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Elanco earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,368 | +10.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 54.0 | +390.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$23.49 −0.25% · −$0.06
Performance +9.7% 1Y
1Y: $21.42 on 17 Oct 2025 → $23.49. High $26.84 (25 Feb 2026), low $19.8 (19 May 2026).
- Previous close
- $23.55
- 52-week range
- $19.8 – $26.84
- One year
- +8.15%
Overview
- Symbol
- ELAN
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Elanco Animal Health Q1 FY26 — Strong Innovation-Driven Growth and Raised Full-Year Outlook
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Elanco Q4 FY25 — Strong Innovation-Led Growth and Accelerated Deleveraging
Read the full callEvery analysed call
Elanco earnings calls (ELAN)
Financials
What the filings say
Net profit, year on year: +391% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,030 | 1,020 | 1,193 | 1,241 | 1,137 | 1,144 | 1,371 | 1,368 |
| Expenses | 471 | 1,071 | — | — | — | — | — | — |
| Other income | -1 | — | — | — | — | — | — | — |
| Interest | 58 | — | — | — | — | — | — | — |
| Profit before tax | 559 | -51 | 60 | 25 | -50 | -259 | 87 | 56 |
| Tax rate | 34.9% | 84.3% | −11.7% | 56.0% | 32.0% | −6.6% | 34.5% | 3.6% |
| Net profit | 364 | -8 | 67 | 11 | -34 | -276 | 57 | 54 |
| EPS ($ per share) | 0.74 | — | 0.14 | 0.02 | -0.07 | — | 0.11 | 0.11 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 16 | 84 | -477 | -979 | -1,057 | -2,288 | -1,950 | -2,182 |
| Total liabilities | 3,759 | 3,439 | 9,217 | 8,970 | 8,202 | 8,139 | 6,518 | 6,811 |
| Fixed assets | 922 | 955 | 1,316 | 1,055 | 999 | 1,026 | 993 | 1,409 |
| Total assets | 8,957 | 8,986 | 17,693 | 16,478 | 15,491 | 14,362 | 12,614 | 13,358 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 487 | 224 | -41 | 483 | 452 | 271 | 541 | 560 |
| Cash from investing | -127 | -235 | -4,779 | -530 | -179 | -169 | 1,158 | -279 |
| Cash from financing | -35 | -305 | 4,954 | 210 | -549 | -83 | -1,492 | -275 |
| Net cash flow | 354 | -333 | 161 | 132 | -293 | 7 | 116 | 77 |
| Capital expenditure | -134 | -140 | -135 | -159 | -171 | -140 | -147 | -276 |
| Free cash flow | 353 | 84 | -176 | 324 | 281 | 131 | 394 | 284 |
ELAN revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Reportable | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +10.2% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
ELAN operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Reorder rate Zenrelia - US | 80%+We're now in about half of the clinics in the US and the reorder rate is over 80%.Source: earnings call transcript | 80%+That's greater than 60% of the total clinic base with a reorder rate maintained at over 80%.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- Non Us 52% ↓ 1 pt
- US 48% ↑ 1 pt
As ELAN cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
84 filings between Nov 28, 2025 and Aug 20, 2026.
Open market
decisions to buy or sellPurchases
$2.61M
11 purchases by 7 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 50
- Award — granted as compensation
- 22
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Kurzius Lawrence Erik | $1.15M | — | Aug 20, 2026 |
| Simmons Jeffrey N | $578.3K | — | May 15, 2026 |
| VanHimbergen Robert M | $247.4K | — | Aug 7, 2026 |
| Herendeen Paul | $236.8K | — | Aug 7, 2026 |
| Modi Rajeev A. | $195.9K | — | May 15, 2026 |
| Harrington Michael J | $109.1K | — | Aug 12, 2026 |
| O'Neill Shiv | $94.3K | — | Aug 18, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Kurzius Lawrence Erik Director | Purchase | 40,000 | $935.9K |
| Aug 18, 2026 | O'Neill Shiv GC AND CORP SEC | Purchase | 3,998 | $94.3K |
| Aug 12, 2026 | Harrington Michael J Director | Purchase | 5,000 | $109.1K |
| Aug 7, 2026 | Herendeen Paul Director | Purchase | 10,000 | $236.8K |
| Aug 7, 2026 | VanHimbergen Robert M EVP and CFO | Purchase | 4,200 | $96.9K |
| Jul 7, 2026 | VanHimbergen Robert M EVP and CFO | Tax withheld | 15,336 | $377.9K |
| May 21, 2026 | Kurzius Lawrence Erik Director | Award | 4,678 | $0 |
| May 21, 2026 | GARCIA ART A Director | Award | 4,678 | $0 |
| May 21, 2026 | Anand Kapila K Director | Award | 4,678 | $0 |
| May 21, 2026 | Scots-Knight Denise Director | Award | 12,196 | $0 |
| May 21, 2026 | Scots-Knight Denise Director | Award | 4,678 | $0 |
| May 21, 2026 | Kochevar Deborah Turner Director | Award | 4,678 | $0 |
| May 21, 2026 | Herendeen Paul Director | Award | 4,678 | $0 |
| May 21, 2026 | Herendeen Paul Director | Award | 12,196 | $0 |
| May 21, 2026 | McDonald Kirk P Director | Award | 12,196 | $0 |
| May 21, 2026 | GARCIA ART A Director | Award | 12,196 | $0 |
| May 21, 2026 | Ma Stacey Director | Award | 12,196 | $0 |
| May 21, 2026 | HOOVER R DAVID Director | Award | 4,678 | $0 |
| May 21, 2026 | Harrington Michael J Director | Award | 12,196 | $0 |
| May 21, 2026 | Kurzius Lawrence Erik Director | Award | 12,196 | $0 |
| May 21, 2026 | Anand Kapila K Director | Award | 12,196 | $0 |
| May 21, 2026 | Ma Stacey Director | Award | 4,678 | $0 |
| May 21, 2026 | Harrington Michael J Director | Award | 4,678 | $0 |
| May 21, 2026 | McDonald Kirk P Director | Award | 4,678 | $0 |
| May 15, 2026 | Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR | Purchase | 4,971 | $99.8K |
| May 15, 2026 | Modi Rajeev A. SEE REMARKS | Purchase | 4,911 | $99.9K |
| Apr 1, 2026 | de Brabander Ellen SEE REMARKS | Award | 40,985 | $0 |
| Apr 1, 2026 | de Brabander Ellen SEE REMARKS | Tax withheld | 20,288 | $469.1K |
| Mar 3, 2026 | Kinard David S SEE REMARKS | Tax withheld | 3,433 | $85.4K |
| Mar 3, 2026 | Cabral Ramiro Martin SEE REMARKS | Tax withheld | 6,492 | $161.5K |
| Mar 3, 2026 | Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR | Tax withheld | 37,898 | $942.9K |
| Mar 3, 2026 | Modi Rajeev A. SEE REMARKS | Tax withheld | 4,392 | $109.3K |
| Mar 3, 2026 | McArdle Grace EVP, MANUFACTURING AND QUALITY | Tax withheld | 4,322 | $107.5K |
| Mar 3, 2026 | Bettington Timothy J SEE REMARKS | Tax withheld | 4,695 | $116.8K |
| Mar 3, 2026 | de Brabander Ellen SEE REMARKS | Tax withheld | 8,262 | $205.6K |
| Mar 3, 2026 | Correia de Simas Jose Manuel SEE REMARKS | Tax withheld | 3,371 | $83.9K |
| Mar 3, 2026 | Meer James M CHIEF ACCOUNTING OFFICER | Tax withheld | 1,389 | $34.6K |
| Mar 3, 2026 | O'Neill Shiv GC AND CORP SEC | Tax withheld | 4,738 | $117.9K |
| Mar 1, 2026 | Cabral Ramiro Martin SEE REMARKS | Award | 60,053 | $0 |
| Mar 1, 2026 | VanHimbergen Robert M EVP and CFO | Award | 23,675 | $0 |
| Mar 1, 2026 | Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR | Award | 119,319 | $0 |
| Mar 1, 2026 | Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR | Award | 397,041 | $0 |
| Mar 1, 2026 | Bettington Timothy J SEE REMARKS | Tax withheld | 18,098 | $477.8K |
| Mar 1, 2026 | Bettington Timothy J SEE REMARKS | Award | 46,322 | $0 |
| Mar 1, 2026 | Meer James M CHIEF ACCOUNTING OFFICER | Award | 5,209 | $0 |
| Mar 1, 2026 | Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR | Tax withheld | 229,982 | $6.07M |
| Mar 1, 2026 | Correia de Simas Jose Manuel SEE REMARKS | Award | 21,507 | $0 |
| Mar 1, 2026 | Meer James M CHIEF ACCOUNTING OFFICER | Tax withheld | 4,787 | $126.4K |
| Mar 1, 2026 | Bettington Timothy J SEE REMARKS | Award | 9,470 | $0 |
| Mar 1, 2026 | Correia de Simas Jose Manuel SEE REMARKS | Tax withheld | 9,883 | $260.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Elanco Animal Health Inc
Free account. Everything above stays public.
Write why you follow Elanco Animal Health Inc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading